Fore Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-25,000
Closed -$2.47M 59
2024
Q3
$2.47M Buy
+25,000
New +$2.46M 1.03% 15
2021
Q3
Sell
-5,000
Closed -$677K 76
2021
Q2
$677K Buy
+5,000
New +$657K 0.21% 50

Other funds holding XBI

Fore Capital's XBI Position: Q4 2024 in Review

Fore Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2024, closing a stake of 25,000 shares — an estimated $2.47M sold.

Fore Capital first reported a position in XBI in Q2 2021 and held it in 2 quarters. The position peaked at $2.47M in Q3 2024. 738 funds tracked by Wall St. Rank hold XBI as of Q4 2024.

  • Fore Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2024 after selling out during the quarter.
  • Fore Capital sold 25,000 State Street SPDR S&P Biotech ETF shares in Q4 2024, an estimated $2.47M.
  • Fore Capital first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and held it in 2 quarters.
  • Fore Capital's State Street SPDR S&P Biotech ETF position peaked at $2.47M in Q3 2024.
  • 738 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2024.

Based on Fore Capital's 13F filing for Q4 2024, filed 10 Feb 2025.